Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Safety and Durable Immunogenicity of Melanoma Vaccination, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

NCT03617328 is registered in ClinicalTrials.gov with Craig L Slingluff, Jr as lead sponsor.

NCT NCT03617328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03617328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Safety and Durable Immunogenicity of Melanoma Vaccination, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma
Lead sponsor
Craig L Slingluff, Jr
Phase
Phase 1/2
Overall status
Completed
Start date
November 13, 2018
Completion date
January 19, 2024
Enrollment
33 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma